Medical writer: Kara Nyberg, PhD
Ado-trastuzumab emtansine, the antibody-drug conjugate more commonly known as T-DM1, demonstrated robust activity in HER2-amplified salivary gland cancer (SGC) within a phase II basket trial, warranting further investigation in this disease (Abstract 6001). Among the 10 patients with SGC treated with T-DM1, nine obtained an objective response, six of which were complete responses.
The median duration of response and median progression-free survival have yet to be reached despite a median follow-up of 12 months (range: 4 to 20 months).
To gain ground in this rare malignancy, researchers are capitalizing on the targetable mutations offered up by the diverse molecular landscape of SGC. HER2 gene amplification identified through next-generation sequencing (NGS) occurs in 8% of patients with SGC and approximately 30% of patients with the aggressive salivary duct carcinoma histologic subtype.1 B...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« KEYNOTE-062: Pembrolizumab Combination Fails to Improve Survival in Gastric/GEJ Cancer Next Article
Daratumumab a Promising Treatment Option for Transplant-eligible Multiple Myeloma »
Table of Contents: ASCO 2019
Head and Neck Cancer
Genitourinary Cancer - Prostate Cancer
Developmental Therapeutics - Immunotherapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.